Background: organophosphates are widely used in agriculture as pesticides, in industry and as household chemicals, allowing many opportunities for acute poisoning, as well as for occupational use. Besides, organophosphates being nerve agents are used in military setting or in terrorist attacks. Fifty years after first use, we still do not know what the optimum treatment for organophosphate toxicity is. Small studies suggest benefit from new treatments such as magnesium sulphate, but much larger trials are needed. The aim of the study was to evaluate the effect of i.v. Magnesium sulphate on mortality rate in acute organophosphate toxicity. Patients and methods: a comparative study in which iv magnesium sulphate was given in a dose of 1g/6hrs for 24hrs to 50 patients acutely intoxicated with organophosphate who are treated with atropine and oximes (group i) and compared to 50 patients who are not given iv magnesium sulphate who are treated with atropine and oximes then mortality rate in the two groups are compared. Results: comparison between the control and the group which took magnesium sulphate showed a statistical significant difference between the 2 groups in the mortality rate (p<0.05). Conclusion: magnesium sulphate decreases mortality rate in acute organophosphate toxicity .such information may in turn guide clinical practice to the use of magnesium sulphate in acute organophosphate toxicity and so more studies should be done to confirm these findings.
INTRODUCTION
Pesticides result in a huge number of intoxications because of their widespread use and easy accessibility especially in the developing world's agricultural communities and constitute high share of intoxicated patients worldwide, since the only life-saving antidotes for ChE-I pesticide poisoning are oxygen and atropine, the most important issue after resuscitation is to decide the need for atropine. The clinical features of cholinergic poisoning are the trigger for the decision to give atropine (Ballantyne and Marrs, 1992 The diagnosis of acute OP poisoning was based upon history of oral ingestion of a known OP, presence of characteristic symptoms and signs of muscarinic and nicotinic involvement, and reduced levels of plasma choline esterase.
Patients were excluded from the study if they had concomitant ingestion of other drugs in a suicidal attempt. Patients were divided into two groups and in a systematic sampling, every second eligible patient was chosen to undergo MgSO4 treatment.
We studied 100 patients (56 females, 44 male). Group I consists of fifty patients (25 males, 25 females) received magnesium sulphate ivi (1g/6hr for first 24 hrs) beside the routine treatment comprising of gastric lavage, administration of 1 g/kg activated charcoal and serial administration of activated charcoal, bathing with water and soap at least three times a day, appropriate bolus and maintenance doses of atropine (the endpoint of atropinization was drying of secretions, flashing, tachycardia and mydriasis), and appropriate doses of obidoxime. Group II consists of fifty patients (31 females, 19 males) received the routine treatment without magnesium sulphate.
The starting dose of obidoxime was 250-500mg IV Additional doses were given in a bolus of 250-500 mg IV over 30-60 min every 6-12 hours according to severity of poisoning. The ideal dose of obidoxime was determined by monitoring the clinical condition of the patient and serial assessment of cholinesterase levels over a period of several days.
RESULTS
Assessment of plasma choline esterase level (BuChE) levels spectrophotometrically in both groups showed no statistically significant difference between group I and group II in plasma choline esterase level on admission (p>0.05) ( Table 1) . 
DISCUSSION
Hypomagnesemia and resistance to atropine have been detected in a group of cattle but this finding has not been repeated in either animals or humans (Sungur and Guven, 2001) .
In our study, on admission there was no statistical difference between the 2 groups in BuChE activity in plasma and this is consistent with 
CONCLUSIONS
It is recommended to infuse magnesium sulphate in a dose of 1g/6 hrs in acute organophosphate toxicity to reduce mortality rate.
Adequate follow up and monitoring of either regimens administered and adequate titration to symptoms may play an important role for clinical improvement of intoxicated patients.
There is other many factors that affect the improvement of the clinical presentations of CHE-I poisoning besides the treatment regimen as type of organophosphate and delay before medical management. 
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